Donate Tissue

Tag: FEATURED

  • Endeavour Cells investment in Cell2Cure

    Endeavour Cells investment in Cell2Cure

    Cell2Cure has January 2024 received a significant equity investment from Endeavour Cell ApS, to further develop our collaboration.

    Endeavour Cells will own 51% of the company. In addition to the invested capital the collaboration with Endeavor Cells includes milestone payments and potential continued financing of Cell2Cure’s activities within a 5-year time frame.

    This collaboration will further consolidate Cell2Cure and strengthen the technological, clinical and commercial development of our very promising stem cell treatment technology.

    The overall goal for Cell2Cure is to establish stem cells as a new treatment option for several disease indications for the benefit of the patients and the society.

    Press release (in danish)

  • Cell2Cure is partner in an EU-funded project, RESTORE VISION, within rare eye diseases

    Cell2Cure is partner in an EU-funded project, RESTORE VISION, within rare eye diseases

    In Europe, approximately 30 million people suffer from blindness and visual impairment. Rare Eye Diseases are a major cause that can result in blindness in children and young adults and affect adults and the ageing population. Current management is expensive, has low efficacy, and significant side effects.

    The consortium – RESTORE VISION – aims to address this clinical need by formulating novel treatments and repurposed drugs that have been validated in different disease indications (Home – Restore vision).

    The project will target seven rare eye diseases: aniridia-associated keratopathy; neurotrophic keratopathy; limbal stem cell deficiency; ocular cicatricial pemphigoid; EEC syndrome; ocular graft versus host disease; and corneal neovascularisation.

    Cell2Cure participate in the consortium with the patented cell product: allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) and our expertise within conduction of clinical trials.

    The ASC products will be tested in a clinical trial as an immunosuppressive treatment in patients with ocular graft versus host disease.

  • Cell2Cure has treated the first patients with autism spectrum disorders and signs of leaky gut syndrome in a Phase I trial

    Cell2Cure has treated the first patients with autism spectrum disorders and signs of leaky gut syndrome in a Phase I trial

    The first two children with autism spectrum disorder (ASD) and signs of leaky gut syndrome has been treated with allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) at Aalborg University Hospital without any complication.

    The trial is a collaboration between Cell2Cure and Professor Marlene Briciet Lauritsen, Department of Child and Adolescent Psychiatry, Aalborg University, Aalborg University Hospital, and Endeavour Cells ApS, who holds the C2C_ASC sublicense from Cell2Cure for this indication.

    The trial hypothesis is that the connection between gastrointestinal symptoms/leaky gut syndrome increases local gastrointestinal and systemic elevated immunological and inflammatory activity, bacterial toxins in the blood and symptoms of ASD in children with symptoms of leaky gut syndrome can be reduced or normalized by modulating the immunological activity and inflammation by treatment with ASCs.

    This phase I clinical trial is investing the safety and efficacy of treatment with Cell2Cure’s ASC products. In the trial a total of 10 children with autism and signs of leaky gut syndrome will be enrolled. The children will be treated with intravenous infusion of 1 million ASCs per Kg body weight or 2 million ASCs per Kg body weight.

    Endeavour Cells is financial sponsor of the trial, and Cell2Cure is the clinical sponsor.

    This treatment concept has the potential to become a pioneering treatment of children with autism spectrum disorders and signs of leaky gut syndrome.